Literature DB >> 31029962

Heart rate variability mediates the association between polycyclic aromatic hydrocarbons exposure and atherosclerotic cardiovascular disease risk in coke oven workers.

Liangle Yang1, Wenting Guo1, Dan Zeng2, Lin Ma1, Xuefeng Lai1, Qin Fang1, Huan Guo1, Xiaomin Zhang3.   

Abstract

Polycyclic aromatic hydrocarbons (PAHs) metabolites was related to heart rate variability (HRV) reduction and atherosclerotic cardiovascular disease (ASCVD), and ASCVD was also affected by HRV. However, the mediating role of HRV in the association between PAHs exposure and ASCVD risk was largely unknown. We aimed to investigate whether the relation of PAHs exposure with ASCVD risk was mediated by HRV among coke oven workers. A total of 1100 subjects with complete data were qualified in the current study. We measured 12 urinary PAHs metabolites by gas chromatography-mass spectrometry (GC-MS) and HRV indices by 3-channel digital Holter monitors. The associations between urinary PAHs metabolites, HRV indices, and ASCVD risk were explored using generalized linear models or multivariate logistic regression models. A mediation analysis was conducted to examine the role of HRV on the association between PAHs exposure and ASCVD risk. We found that urinary 1-hydroxynaphthalene (1-OHNa), 2-OHNa, and total PAH metabolites (ΣOH-PAH) were dose-responsive associated with increased risk of ASCVD. Compared with lowest quartile, the adjusted odds ratio (OR) for ASCVD risk in the highest quartile were 2.36 for 1-OHNa, 6.58 for 2-OHNa, and 1.60 for ΣOH-PAH (all Ptrend<0.05). In addition, significant dose-dependent relationships were found across 2-OHNa quartiles with decreasing HRV indices, which in turn, were positively associated with elevated risk of ASCVD (all Ptrend<0.05). Mediation analyses indicated that HRV mediate 2.7%-4.3% of the association between 2-OHNa exposure and higher ASCVD risk. Our data suggested that occupational exposure to PAHs may increase ASCVD risk, which was partially mediated by HRV.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Atherosclerotic cardiovascular disease; Heart rate variability; Mediation; Polycyclic aromatic hydrocarbons

Mesh:

Substances:

Year:  2019        PMID: 31029962     DOI: 10.1016/j.chemosphere.2019.04.101

Source DB:  PubMed          Journal:  Chemosphere        ISSN: 0045-6535            Impact factor:   7.086


  6 in total

1.  Source identification and risk assessment of polycyclic aromatic hydrocarbons (PAHs) in air and dust samples of Lahore City.

Authors:  Rabia Aslam; Faiza Sharif; Mujtaba Baqar; Laila Shahzad
Journal:  Sci Rep       Date:  2022-02-14       Impact factor: 4.379

2.  The Association between Urinary Polycyclic Aromatic Hydrocarbons Metabolites and Type 2 Diabetes Mellitus.

Authors:  Xue Wang; Ang Li; Qun Xu
Journal:  Int J Environ Res Public Health       Date:  2022-06-22       Impact factor: 4.614

3.  Clinical Relevance of Urine Flow Rate and Exposure to Polycyclic Aromatic Hydrocarbons.

Authors:  Po-Hsuan Jeng; Tien-Ru Huang; Chung-Ching Wang; Wei-Liang Chen
Journal:  Int J Environ Res Public Health       Date:  2021-05-18       Impact factor: 3.390

Review 4.  The aryl hydrocarbon receptor as a target of environmental stressors - Implications for pollution mediated stress and inflammatory responses.

Authors:  Christoph F A Vogel; Laura S Van Winkle; Charlotte Esser; Thomas Haarmann-Stemmann
Journal:  Redox Biol       Date:  2020-04-18       Impact factor: 10.787

5.  Environmental Monitoring of PAHs Exposure, Biomarkers and Vital Status in Coke Oven Workers.

Authors:  Luigi Vimercati; Lucia Bisceglia; Domenica Cavone; Antonio Caputi; Luigi De Maria; Maria Celeste Delfino; Vincenzo Corrado; Giovanni Maria Ferri
Journal:  Int J Environ Res Public Health       Date:  2020-03-25       Impact factor: 3.390

6.  Relationship Between Polycyclic Aromatic Hydrocarbons and Cardiovascular Diseases: A Systematic Review.

Authors:  Manthar Ali Mallah; Mukhtiar Ali Mallah; Yang Liu; He Xi; Wei Wang; Feifei Feng; Qiao Zhang
Journal:  Front Public Health       Date:  2021-12-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.